Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2007

Biovail Gains License to Two Pharma Pass II Early-Stage Compounds

  • Biovail acquired the worldwide rights to two reportedly early-stage candidates from Pharma Pass II (PPII). BVF-068 is being investigated for the treatment of a central nervous system (CNS) disorder, and BVF-247 is a novel formulation of a cardiovascular agent, according to the companies.

    Biovail will develop, manufacture, and market both compounds. PPII will receive an upfront fee, milestone payments for each product, and tiered, single-digit royalties on net commercial sales.

    “These two products target large global markets and have the potential to address safety issues inherent in the currently marketed formulations,” points out Douglas Squires, Ph.D., Biovail's CEO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »